HOME >> BIOLOGY >> NEWS
March of Dimes awards $250,000 prize to research pioneer

WHITE PLAINS, N.Y. MAY 1, 2006 -- For explaining how a tiny protein plays a major role in our lives by helping to regulate many crucial processes in human cells, Alexander Varshavsky, Ph.D., has been chosen as the 2006 recipient of the March of Dimes Prize in Developmental Biology, to be awarded May 1 in San Francisco, California.

The March of Dimes Prize is a cash award of $250,000 and a silver medal in the design of the Roosevelt dime, in honor of President Franklin Delano Roosevelt, who founded the March of Dimes.

Dr. Varshavsky, the Howard and Gwen Laurie Smits Professor of Cell Biology in the Division of Biology at the California Institute of Technology, has been credited by his peers with co-founding the field of ubiquitin research and ushering it into the age of molecular genetics. His pioneering studies in the 1980s brought to light the remarkably diverse and important biological functions of the ubiquitin system.

Ubiquitin (from the Latin ubique meaning "everywhere," the source of the word "ubiquitous"), is a protein found in every cell of all living things, from yeast to human beings. It attaches itself to many other proteins in cells specifically those proteins that have outlived their purpose, or are abnormal, or must be destroyed to regulate their levels in a cell. Ubiquitin marks these proteins for destruction by a protein-degrading molecular "machine" called the proteasome.

Dr. Varshavsky's laboratory discovered that ubiquitin plays important roles in the cell cycle, DNA repair, protein synthesis, transcriptional regulation, and responses to stress. Dr. Varshavsky and coworkers also discovered "degradation" signals in short-lived proteins, the source of ubiquitin's selectivity as well as a fundamental property of the ubiquitin system that makes it possible to remodel multi-subunit proteins by destroying them partially, "one subunit at a time." His work revealed that the regulation of cells through selective
'"/>

Contact: Elizabeth Lynch
elynch@marchofdimes.com
914-997-4286
March of Dimes Birth Defects Foundation
10-Apr-2006


Page: 1 2

Related biology news :

1. March of the giant penguins
2. March of Dimes awards $250K prize to stem cell research, reproductive biology pioneers
3. ACS News Service Weekly PressPac -- March 28, 2007
4. ACS News Service Weekly PressPac -- March 21, 2007
5. National Academies advisory: March 27 release of report on metagenomics
6. JCI table of contents -- March 22, 2007
7. Other highlights from the March 21 JNCI
8. Story tips from the Department of Energys Oak Ridge National Laboratory, March 2007
9. Research and program highlights of the 2007 Annual Clinical Genetics Meeting, March 21-25, 2007
10. ACS News Service Weekly PressPac -- March. 14, 2007
11. Pioneering researcher Dr. Kenneth Lyons Jones receives genetics award from March of Dimes

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: March Dimes awards prize research pioneer

(Date:8/19/2015)... HAUPPAUGE, N.Y. , Aug. 19, 2015 /PRNewswire/ ... announced that it has entered into a Definitive ... intellectual property, of iris authentication market leader EyeLock ... transaction, VOXX will have a controlling interest in ... is subject to completion of due diligence.  Expanding ...
(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions ... the entire spectrum of clinical research, is proud to ... the company,s comprehensive SaaS-based eClinical technology platform, has led ... the first two quarters of 2015.   Q2 2015 ... largest quarters measured by contract value sold in the ...
(Date:8/11/2015)... , August 11, 2015 Today, ZUK ... Already received as well as expected revenues in 2015 that relate ... FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a prominent smartphone manufacturer in ... ZUK selected FPC1 155 for ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5MedNet Solutions Experiences Explosive Corporate Growth 2FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2
(Date:8/26/2015)... ... August 26, 2015 , ... Lee ... in the development and manufacture of highly valued cardiac markers used in early ... extensive expertise with protein chemistry has led to the development and commercialization of ...
(Date:8/26/2015)... GERMANTOWN, Md. , Aug. 26, 2015 ... synthetic biology, announced today the closing of its previously ... in full by the underwriters of their option to ... the public offering price of $41.00 per share.  The ... of shares of common stock sold by Intrexon to ...
(Date:8/26/2015)... , August 26, 2015 After litigating ... Europlasma NV relating to P2i United States ... their dispute in the United States ... the part of either party. As a result of the ... of California dismissed the case without ...
(Date:8/26/2015)... ... 2015 , ... The 2015 Epigenomics & Metabolomics Meeting in Boston ... Asymmetrex to share the first report on progress with its crowdsourcing campaign designed ... tissue stem cells. , With a name like “H2A.Z asymmetry,” the new biomarker would ...
Breaking Biology Technology:Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4P2i Settles United States Litigation 2Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 2Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 3Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 4
Cached News: